Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Ryvu Therapeutics SA
RVUCurrent price
47.55 PLN
-0.35 PLN (-0.73%)
Last closed
48.6 PLN
Company
www.ryvu.com
ISIN
PLSELVT00013
Sector
Healthcare
Industry
Biotechnology
Exchange
Warsaw Stock Exchange
Capitalization
997 129 714 PLN
Yield for 12 month
-16.14 %
1Y
3Y
5Y
10Y
15Y
RVU
Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, synthetic lethality, and immuno-oncology. The company has a research collaboration with Ncage Therapeutics Limited to develop next-generation antibody-drug conjugate (ADC) platform. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland. Address: Leona Henryka Sternbacha 2, Kraków, Poland, 30-394
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
323.1 PLNP/E ratio
–Dividend Yield
–Current Year
+47 000 791 PLN
Last Year
+38 920 588 PLN
Current Quarter
+15 792 307 PLN
Last Quarter
+21 670 916 PLN
Current Year
+29 394 051 PLN
Last Year
+21 462 289 PLN
Current Quarter
+12 036 056 PLN
Last Quarter
+16 810 356 PLN
Key Figures RVU
1 year
3 years
5 years
10 years
EBITDA
-95 532 168 PLN
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-15.56 %
PEG Ratio
–
Return On Equity TTM
-44.88 %
Wall Street Target Price
323.1 PLN
Revenue TTM
91 452 950 PLN
Book Value
7.38 PLN
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
54.1 %
Dividend Yield
–
Gross Profit TTM
23 425 035 PLN
Earnings per share
-4.21 PLN
Diluted Eps TTM
-4.21 PLN
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-114.21 %
Dividend Analytics RVU
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RVU
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation RVU
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
13.1757
Price Sales TTM
10.9032
Enterprise Value EBITDA
-12.7108
Price Book MRQ
4.8399
Financials RVU
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RVU
For 52 weeks
39.62 PLN
67.3 PLN
50 Day MA
51.07 PLN
Shares Short Prior Month
–
200 Day MA
53.36 PLN
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart